| 000 | 01219 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250516084102.0 | ||
| 264 | 0 | _c20120724 | |
| 008 | 201207s 0 0 eng d | ||
| 022 | _a1540-336X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPostow, Michael A | |
| 245 | 0 | 0 |
_aTargeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. _h[electronic resource] |
| 260 |
_bCancer journal (Sudbury, Mass.) _c |
||
| 300 |
_a153-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCTLA-4 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 | _aIpilimumab |
| 650 | 0 | 4 |
_aMelanoma _ximmunology |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHarding, James | |
| 700 | 1 | _aWolchok, Jedd D | |
| 773 | 0 |
_tCancer journal (Sudbury, Mass.) _gvol. 18 _gno. 2 _gp. 153-9 |
|
| 999 |
_c21656321 _d21656321 |
||